Sep 15, 2022 | 2022, Press Releases, Scientific
The study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to non-human primates. More detailsJul 25, 2022 | 2022, Press Releases, Scientific
More detailsJun 27, 2022 | 2022, Past Events, Scientific
Philogen will attend the 3rd Annual Cytokine-Based Drug Development Summit in Boston. Roberto De Luca, Head of Antibody Therapeutics, will give a virtual lecture entitled “Antibody-cytokine fusion proteins against Fibroblast Activation Protein (FAP)” on the 28...Feb 17, 2022 | 2022, Press Releases, Scientific
More detailsJan 7, 2022 | 2022, Press Releases, Scientific
More info hereNov 24, 2021 | 2021, Press Releases, Scientific
More datails
Recent Comments